Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is a promising investment opportunity with the potential to revolutionize CAR-T therapy and enter new markets due to its EB103 technology platform. This platform addresses limitations of current CD19 CAR-T therapies and has shown promising data in Phase I trials. The company's entry into Phase II trials and expected generation of additional clinical data further strengthens its potential success and adds to its valuation as a sound investment opportunity.

Bears say

Estrella Immunopharma is facing multiple risks including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks, which could negatively impact their milestone and royalty revenue. Their recent capital raise may support their short-term clinical execution, but their declining stock price raises concerns about future dilution and signals potential updates on partnering and pipeline prioritization. As a financial analyst, a recommended conservative stance would be to lower the target price for the stock from $16.0 to $8.0.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.